GovChime
Notice ID: 30ab6f2e83cb477e8b42873b57c02b6bCombined Synopsis/Solicitation

Atropine & Pralidoxime Chloride Injector, Single Dose Auto- Injectors

Archived on September 6, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
4:00 PM UTC−04:00
Posted
August 8, 2024
Notice type
Combined Synopsis/Solicitation
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Health and Human ServicesOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

Notice details

Office
ASPR/ORM-SNS
Place of performance
Washington, DC, 20201
Last updated
Dec 4, 2025

Identifiers

Solicitation number
75A50324R00005
Notice ID
30ab6f2e83cb477e8b42873b57c02b6b

Description

The Strategic National Stockpile (SNS), of the U.S. Department of Health and Human Services (HHS) Office of the Administration for Strategic Preparedness and Response (ASPR), has a requirement for Atropine & Pralidoxime Chloride Injector, Single Dose Auto-Injectors. Refer to attached request for proposal (RFP).

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75A50324R00005
  1. Combined Synopsis
  1. Combined SynopsisCurrentAug 8, 2024

    Atropine & Pralidoxime Chloride Injector, Single Dose Auto- Injectors

    Notice 30ab6f2e83cb477e8b42873b57c02b6b on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Please see attached for the sources sought notice/market research survey and MPID.
57%
Market Research11/30/2026
The Defense Logistics Agency is issuing a solicitation for a national requirements contract for Epinephrine Injectors. Procurement details follow. Epinephrine 0.3 MG/0.3 ML Injection, Auto-Injector 2S in 2 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Jeremy Brown at (445) 737-5419, (jeremy.brown@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current solicitation date is October of 2026.
43%
Solicitation11/30/2026
Sources-Sought Notice The Indian Health Service, Crownpoint Service Unit is issuing this sources-sought notice (SSN) to identify capable Indian-owned, economic enterprises – large (IEE) or small (ISBEE) – that can provide A Blanket Purchase Agreement for IV fluids on an “As Needed Basis” for the General Services Department. This will be issued as a Base Year plus (4) Option Years. Other capable firms are also invited to respond to this SSN. The Contracting Officer will consider responses for Buy Indian Act (25 U.S.C. 47) opportunities first, then for set aside programs under the Small Business Act (41 U.S.C. 3104). The applicable North American Industry Classification System (NAICS) code assigned to this requirement is 325412- Pharmaceutical Preparation Manufacturing with a small business size standard of 1300 Employees. THIS IS NOT A SOLICITATION. Information collected from this notice is purely for market research only and will be used to determine the contracting office’s acquisition strategy including competition, set asides, and locating Indian-owned economic enterprises. Submission of any information in response to this market survey is purely voluntary. The government assumes no financial responsibility for any costs incurred in response to this request for information. In accordance with FAR 4.203-1(b), offerors and quoters must be registered in System for Award Management at SAM.gov, at the time an offer or quotation is submitted and at time of award. Submission Instructions: Interested parties who consider themselves qualified to perform the above-listed services are invited to submit a response to this notice by November 23, 2026, 8:00am MT to Arlynda Largo at Arlynda.largo@ihs.gov with the subject line “SSN-CPSU-1533180- BPA for IV Fluids on an “As Needed Basis”. Your submission must include the following information, at a minimum: 1. Company Profile that includes: UEI, Name and Address, Primary POC information, business size and type of ownership, socio-economic status/participation such as 8(a), WOSB/EDWOSB, SDVOSB and HUBZone, identification of Native American ownership, SAM.gov representations and certifications, and other related documentation. 2. A brief statement of the company’s capability that relates to the described government requirement. Additional demonstration of capability may include current and past performance history for the same or similar requirement, established contracts such as GSA or VA Schedule, etc. 3. Indian-owned Small Business Economic Enterprises (ISBEEs) and Indian-owned Economic Enterprises (IEEs) must also submit a completed IHS IEE Representation Form (attached) in accordance with HHSAR 326.606-1(b).
35%
Market Research11/23/2026
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
35%
Pre-Solicitation11/11/2026

Additional Details

Solicitation Number

75A50324R00005

Archive Date

Sep 6, 2024

Office Address

Atlanta, GA, 30341